PRedictive Accuracy of Initial Stone Burden Evaluation.
Launched by UNIVERSITY HOSPITAL, GHENT · Feb 8, 2021
Trial Information
Current as of August 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The current EAU and AUA guidelines still base the recommendations for stone treatment on cumulative stone diameter, a linear measurement of the stone burden. Multiple nomograms rather use the stone burden's surface area to predict post-operative outcomes. More recently, volume has been prposed as the most accurate measure of stone burden and the variable to be reported in stone treatment literature. Although inuitively a three dimensional evaluation is most likely the most accurate representation of the stone burden to be treated.
Several reports however have compared different ways of mea...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Availability of computed tomography imaging
- • Undergoing any of the previously described procedures: extracorporeal shockwave lithotripsy, uretero(reno)scopy or percutaneous nephrolithotomy
- • Able to read and understand the information regarding the study and able to provide informed consent
- Exclusion Criteria:
- • Under the stated age limit
- • No pre-operative computed tomography imaging available
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, Eastern Flanders, Belgium
Patients applied
Trial Officials
Thomas Tailly, MD
Principal Investigator
University Hospital, Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials